Join EHC 2026 Annual Conference
EHC – European Haemophilia Consortium shared a post on LinkedIn:
”Join us at the EHC 2026 Annual Conference in Istanbul, hosted by Turkish Hemophilia Society.
Although von Willebrand Disease (VWD) is the most common inherited bleeding disorder, it’s still too often overlooked, leading to real challenges in diagnosis, treatment, and long-term care.
Don’t miss this dedicated session exploring the most important topics affecting people living with VWD today:
- Jeroen Eikenboom (Leiden University) provides an update on the latest developments in VWD treatment
- Sebastien L. (Cliniques Universitaires Saint-Luc) examines the relationship between joint health and VWD
- Milica Dimic brings the patient voice to the discussion, sharing her perspective on prophylaxis and the impact treatment decisions can have on daily life
By combining scientific advances with patient experience, this session offers valuable insights into the evolving landscape of VWD care and the importance of a more personalised approach to treatment.
Don’t miss this opportunity to be part of the conversation.
Stay updated with Hemostasis Today.
-
Oct 8, 2026, 04:28Jeff Molter: Electrophysiological PIEZO1 Analysis Advances Diagnosis in Hereditary Xerocytosis
-
Oct 8, 2026, 04:23Barbara Adams Krolak: Women and Blood Clots Are We Missing the Warning Signs
-
Oct 8, 2026, 04:10Rutendo Muzambi: Hospital Admission Patterns and Care Disparities in Sickle Cell Disease
-
Oct 8, 2026, 03:50Olfat Berro: Redefining the Future of Haemophilia A
-
Oct 8, 2026, 03:35Tasnia Tarana: Heavy Menstrual Bleeding When the Cause Is Not in the Uterus
-
Oct 8, 2026, 03:28Kian Haseli: Electrophysiological PIEZO1 Analysis Advances Diagnosis in Hereditary Xerocytosis
-
Oct 8, 2026, 03:20Sthanu Subramanian: Leukopenia in Sepsis A Marker of Severe Disease
-
Oct 7, 2026, 16:44Amor Salah: 2026 NCS/SCCM Guidelines for Managing Antithrombotic-Associated ICH
-
Oct 7, 2026, 16:04NETs in Thrombosis: From Mechanism to Therapeutic Target